Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge J Castillo

Showing results (301-310 of 343) with videos related to

Pageof 35
Sort By:
American Journal of Hematology|March 10, 2025
Depth of Response From Fixed-Duration Treatment Is Associated With Superior Survival in Waldenstrom MacroglobulinemiaJonas Paludo, Jithma P Abeykoon, Nirosha D Perera, et al.
Blood Cancer Journal|February 2, 2020
SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomasManit Munshi, Xia Liu, Jiaji G Chen, et al.
British Journal of Haematology|December 15, 2015
Clonal architecture of CXCR4 WHIM-like mutations in Waldenström MacroglobulinaemiaLian Xu, Zachary R Hunter, Nicholas Tsakmaklis, et al.
Haematologica|November 12, 2020
A prognostic index predicting survival in transformed Waldenström macroglobulinemiaEric Durot, Lukshe Kanagaratnam, Saurabh Zanwar, et al.
Journal of Geriatric Oncology|July 7, 2023
Real-world experience in older patients with diffuse large B-cell lymphoma treated in Latin America: A study by the Latin American study group of lymphoproliferative disorders (GELL)Myrna Candelaria, Luis Villela, Maria-Alejandra Torres-Viera, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2024
Simplified Risk Stratification Model for Patients With Waldenström MacroglobulinemiaSaurabh Zanwar, Jennifer Le-Rademacher, Eric Durot, et al.
The Lancet. Oncology|December 14, 2016
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trialMeletios A Dimopoulos, Judith Trotman, Alessandra Tedeschi, et al.
Blood Advances|March 7, 2022
A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomasManit Munshi, Xia Liu, Amanda Kofides, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 30, 2021
POEMS Syndrome: Real World Experience in Diagnosis and Systemic Therapy - 108 Patients Multicenter AnalysisArtur Jurczyszyn, Jorge J Castillo, Magdalena Olszewska-Szopa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2022
More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple MyelomaTomas Jelinek, Renata Bezdekova, David Zihala, et al.
Pageof 35

Showing results (301-310 of 343) with videos related to

Sort By:
Pageof 35
American Journal of Hematology|March 10, 2025
Depth of Response From Fixed-Duration Treatment Is Associated With Superior Survival in Waldenstrom MacroglobulinemiaJonas Paludo, Jithma P Abeykoon, Nirosha D Perera, et al.
Blood Cancer Journal|February 2, 2020
SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomasManit Munshi, Xia Liu, Jiaji G Chen, et al.
British Journal of Haematology|December 15, 2015
Clonal architecture of CXCR4 WHIM-like mutations in Waldenström MacroglobulinaemiaLian Xu, Zachary R Hunter, Nicholas Tsakmaklis, et al.
Haematologica|November 12, 2020
A prognostic index predicting survival in transformed Waldenström macroglobulinemiaEric Durot, Lukshe Kanagaratnam, Saurabh Zanwar, et al.
Journal of Geriatric Oncology|July 7, 2023
Real-world experience in older patients with diffuse large B-cell lymphoma treated in Latin America: A study by the Latin American study group of lymphoproliferative disorders (GELL)Myrna Candelaria, Luis Villela, Maria-Alejandra Torres-Viera, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2024
Simplified Risk Stratification Model for Patients With Waldenström MacroglobulinemiaSaurabh Zanwar, Jennifer Le-Rademacher, Eric Durot, et al.
The Lancet. Oncology|December 14, 2016
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trialMeletios A Dimopoulos, Judith Trotman, Alessandra Tedeschi, et al.
Blood Advances|March 7, 2022
A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomasManit Munshi, Xia Liu, Amanda Kofides, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 30, 2021
POEMS Syndrome: Real World Experience in Diagnosis and Systemic Therapy - 108 Patients Multicenter AnalysisArtur Jurczyszyn, Jorge J Castillo, Magdalena Olszewska-Szopa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2022
More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple MyelomaTomas Jelinek, Renata Bezdekova, David Zihala, et al.
Pageof 35